Search

Your search keyword '"Mattison, Donald R"' showing total 664 results
Start Over Author "Mattison, Donald R"
664 results on '"Mattison, Donald R"'

4. Contributors

Author

Abdelwahab, Mahmoud, primary, Ahmed, Mahmoud S., additional, Armstrong, Sarah, additional, Berlin, Cheston M., additional, Best, Brookie M., additional, Bottone-Post, Carolyn, additional, Clark, Shannon M., additional, Costantine, Maged M., additional, Crobarger, Kala R., additional, Dolin, Cara D., additional, Fisher, Jeffrey W., additional, Flockhart, David A., additional, Fouche-Camargo, Jeffrey S., additional, Fraser, William D., additional, Grasch, Jennifer L., additional, Haas, David M., additional, Halbert, Lee-Ann, additional, Hardy, Isabelle, additional, Harrison, Carmen V., additional, Hebert, Mary F., additional, Hess, Henry M., additional, Komorowski, Janelle, additional, Li, Miao, additional, Lutz, Megan, additional, Mattison, Donald R., additional, Mehta, Darshan, additional, Momper, Jeremiah D., additional, Monsivais, Luis A., additional, Namazy, Jennifer A., additional, Pacheco, Luis, additional, Ramirez-Cruz, Maria P., additional, Rayburn, William F., additional, Reed, Michael D., additional, Robertson, Sharon E., additional, Rytting, Erik, additional, Ryu, Rachel, additional, Saha, Sumona, additional, Schatz, Michael, additional, Schilder, Jeanne M., additional, Seifert, Steven A., additional, Soljak, Harry, additional, Trout, Kimberly K., additional, Waltz, Jennifer, additional, Yang, Xiaoxia, additional, and Youmans, Andrew, additional

Published
2022
Full Text
View/download PDF

6. A matrix for bridging the epidemiology and risk assessment gap

Author

Burns, Carol J., LaKind, Judy S., Mattison, Donald R., Alcala, Cecilia S., Branch, Francesca, Castillo, Juan, Clark, April, Clougherty, Jane Ellen, Darney, Sally P., Erickson, Heidi, Goodman, Michael, Greiner, Matthias, Jurek, Anne M., Miller, Aubrey, Rooney, Andrew A., and Zidek, Angelika

Published
2019
Full Text
View/download PDF

7. Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease.

Author

Crispo, James A. G., Farhat, Nawal, Fortin, Yannick, Perez-Lloret, Santiago, Sikora, Lindsey, Morgan, Rebecca L., Habash, Mara, Gogna, Priyanka, Kelly, Shannon E., Elliott, Jesse, Kohen, Dafna E., Bjerre, Lise M., Mattison, Donald R., Hessian, Renée C., Willis, Allison W., and Krewski, Daniel

Subjects
PARKINSON'S disease, HEART failure, BIBLIOGRAPHIC databases, DOPAMINE agonists, RANDOMIZED controlled trials
Abstract

Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case–control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Cancer Cluster Investigations: Review of the Past and Proposals for the Future

Author

Goodman, Michael, LaKind, Judy S, Fagliano, Jerald A, Lash, Timothy L, Wiemels, Joseph L, Winn, Deborah M, Patel, Chirag, Van Eenwyk, Juliet, Kohler, Betsy A, Schisterman, Enrique F, Albert, Paul, and Mattison, Donald R

Subjects
Health Services and Systems, Health Sciences, Cancer, Rare Diseases, 2.4 Surveillance and distribution, Good Health and Well Being, Cluster Analysis, Forecasting, Humans, Neoplasms, cancer, cluster investigations, cancer biomarkers, case grouping, leukemia, exposome, infection, Toxicology
Abstract

Residential clusters of non-communicable diseases are a source of enduring public concern, and at times, controversy. Many clusters reported to public health agencies by concerned citizens are accompanied by expectations that investigations will uncover a cause of disease. While goals, methods and conclusions of cluster studies are debated in the scientific literature and popular press, investigations of reported residential clusters rarely provide definitive answers about disease etiology. Further, it is inherently difficult to study a cluster for diseases with complex etiology and long latency (e.g., most cancers). Regardless, cluster investigations remain an important function of local, state and federal public health agencies. Challenges limiting the ability of cluster investigations to uncover causes for disease include the need to consider long latency, low statistical power of most analyses, uncertain definitions of cluster boundaries and population of interest, and in- and out-migration. A multi-disciplinary Workshop was held to discuss innovative and/or under-explored approaches to investigate cancer clusters. Several potentially fruitful paths forward are described, including modern methods of reconstructing residential history, improved approaches to analyzing spatial data, improved utilization of electronic data sources, advances using biomarkers of carcinogenesis, novel concepts for grouping cases, investigations of infectious etiology of cancer, and "omics" approaches.

Published
2014

21. Pubertal delay in male nonhuman primates (Macaca mulatta) treated with methylphenidate

Author

Mattison, Donald R., Plant, Tony M., Lin, Hui-Min, Chen, Hung-Chia, Chen, James J., Twaddle, Nathan C., Doerge, Daniel, Slikker,, William, Patton, Ralph E., Hotchkiss, Charlotte E., Callicott, Ralph J., Schrader, Steven M., Turner, Terry W., Kesner, James S., Vitiello, Benedetto, Petibone, Dayton M., and Morris, Suzanne M.

Published
2011

35. The genetic toxicology of methylphenidate hydrochloride in non-human primates

Author

Morris, Suzanne M., Dobrovolsky, Vasily N., Shaddock, Joseph G., Mittelstaedt, Roberta A., Bishop, Michelle E., Manjanatha, Mugimane G., Shelton, Sharon D., Doerge, Daniel R., Twaddle, Nathan C., Chen, James J., Lin, Chien-Ju, Paule, Merle G., Slikker, William, Jr., Hotchkiss, Charlotte E., Petibone, Dayton, Tucker, James D., and Mattison, Donald R.

Published
2009
Full Text
View/download PDF

42. Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR)

Author

Bennett, Charles L., Starko, Karen M., Thomsen, Henrik S., Cowper, Shawn, Sartor, Oliver, Macdougall, Iain C., Qureshi, Zaina P., Bookstaver, P. Brandon, Miller, April D., Norris, LeAnn B., Xirasagar, Sudha, Trenery, Alyssa, Lopez, Isaac, Kahn, Adam, Murday, Alanna, Luminari, Stefano, Cournoyer, Denis, Locatelli, Francesco, Ray, Paul, and Mattison, Donald R.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results